Clinical Report: Evaluation of Triplet Intravenous Chemotherapy Versus Dual Chemotherapy

Overview

This study compares the efficacy and safety of FOLFOXIRI triplet chemotherapy with FOLFIRI combined with hepatic arterial infusion chemotherapy (HAIC) in patients with unresectable colorectal liver metastases.

Background

Colorectal cancer is a leading cause of cancer-related morbidity and mortality globally, with liver metastases presenting significant treatment challenges. Current systemic chemotherapy regimens often yield limited effectiveness against liver-dominant metastatic disease.

Data Highlights

Key Findings

• The FOLFIRI plus HAIC group had a higher disease control rate compared to the FOLFOXIRI group (89.2% vs. 68.7%, p = 0.004).
• Progression-free survival was significantly longer in the FOLFIRI plus HAIC group (10.3 months vs. 8.2 months, p = 0.038).
• The R0 resection rate was higher in the FOLFIRI plus HAIC group (21.5% vs. 9.0%, p = 0.044).
• Median overall survival was numerically longer in the FOLFIRI plus HAIC group (19.5 months vs. 17.9 months), but not statistically significant (p = 0.150).
• Grade 3/4 adverse events were comparable between the two groups, indicating a manageable safety profile.

Clinical Implications

The findings suggest that FOLFIRI combined with HAIC may offer improved disease control and progression-free survival for patients with unresectable colorectal liver metastases. Clinicians should consider these results when evaluating treatment options for this patient population.

Conclusion

Further validation through prospective studies is warranted.

Related Resources & Content

1. The ASCO Post, 2026 -- Adjuvant Hepatic Arterial Infusion After Surgery for Colorectal Liver Metastases
2. The ASCO Post, 2026 -- Triplet Therapy Demonstrates Superior Progression-Free Survival in First-Line dMMR/MSI-H Metastatic Colorectal Cancer
3. Frontiers in Oncology, 2026 -- Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus
4. The ASCO Post, 2021 -- Better Responses to Hepatic Arterial Infusion Therapy Among Patients With KRAS Wild-Type Metastatic Colorectal Cancer
5. Treatment of Metastatic Colorectal Cancer: ASCO Guideline - PMC
6. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial)
7. Treatment of Metastatic Colorectal Cancer: ASCO Guideline - PMC
8. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial
9. The Landmark Series: Hepatic Arterial Infusion Pump Chemotherapy for Colorectal Liver Metastases and Intrahepatic Cholangiocarcinoma. | EBSCOhost